Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Consensus
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
211.93 USD   +0.26%
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
MT
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Evolution of the average Target Price on BIOGEN INC.
Target Price consensus revisions : last 18 months
Recommendations (Chart) BIOGEN INC.
Analyst Recommendations on BIOGEN INC.
05/04Morgan Stanley Adjusts Biogen's Price Target to $285 from $283, Keeps Overweight Rating
MT
05/04Oppenheimer Adjusts Biogen Price Target to $225 From $240, Maintains Outperform Rating
MT
05/04RBC Raises Price Target on Biogen to $251 From $244, Maintains Outperform Rating
MT
05/04Barclays Adjusts Biogen's Price Target to $210 From $219, Keeps Equalweight Rating
MT
05/04Wedbush Trims Biogen's Price Target to $185 From $188, Citing Aduhelm Wind-Down, Maintains..
MT
04/28Wedbush Raises Biogen's Price Target to $188 From $185, Maintains Neutral Rating
MT
04/27UBS Adjusts Biogen Price Target to $244 From $269, Maintains Buy Rating
MT
More recommendations
Analysis
Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 211,93 $
Average target price 242,78 $
Spread / Average Target 14,6%
High Price Target 343,00 $
Spread / Highest target 61,8%
Low Price Target 185,00 $
Spread / Lowest Target -12,7%
Consensus detail
Consensus revision (last 18 months)